• Samsung C&T corrected its disclosure on Samsung Biologics’ rights offering following confirmation of the first-stage offer price.
• Proceeds earmarked for securities acquisitions were revised to KRW 2.66 trillion from KRW 2.71 trillion.
• Indicative offer price for common shares was cut to KRW 1,174,000 from KRW 1,322,000.
• Record date set for Oct. 6, 2026. Final offer price is due Nov. 4, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Samsung C&T Corporation published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261001800695), on October 01, 2026, and is solely responsible for the information contained therein.